Orgenesis Announces Reverse Stock Split
Orgenesis Inc. (Nasdaq:ORGS) has announced a 1-for-10 reverse stock split of its common stock, effective September 24, 2024. The split aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. Trading on a split-adjusted basis will begin on September 25, 2024, under the existing symbol "ORGS".
Key points:
- The number of issued and outstanding shares will reduce from 47,707,849 to approximately 4,770,785
- Total authorized shares will decrease from 145,833,334 to 14,583,333
- No fractional shares will be issued; affected stockholders will receive cash payments
- The split will proportionately affect equity incentive plans, stock options, warrants, and convertible notes
Securities Transfer will manage the exchange process for stockholders with physical certificates.
Orgenesis Inc. (Nasdaq:ORGS) ha annunciato uno split azionario inverso 1-per-10 delle sue azioni ordinarie, efficace dal 24 settembre 2024. Questo split mira a ripristinare la conformità con il requisito di prezzo minimo di offerta di Nasdaq di $1.00 per azione. Le negoziazioni basate sullo split avranno inizio il 25 settembre 2024, sotto il simbolo esistente "ORGS".
Punti chiave:
- Il numero di azioni emesse e in circolazione verrà ridotto da 47.707.849 a circa 4.770.785
- Il totale delle azioni autorizzate diminuirà da 145.833.334 a 14.583.333
- Non verranno emesse azioni frazionarie; gli azionisti interessati riceveranno pagamenti in contanti
- Lo split influenzerà in modo proporzionale i piani di incentivazione azionaria, le opzioni su azioni, i warrant e le note convertibili
Securities Transfer gestirà il processo di scambio per gli azionisti con certificati fisici.
Orgenesis Inc. (Nasdaq:ORGS) ha anunciado un split inverso de acciones 1-por-10 de sus acciones comunes, vigente a partir del 24 de septiembre de 2024. El split tiene como objetivo recuperar el cumplimiento con el requisito de precio mínimo de oferta de Nasdaq de $1.00 por acción. Las operaciones ajustadas por el split comenzarán el 25 de septiembre de 2024, bajo el símbolo existente "ORGS".
Puntos clave:
- El número de acciones emitidas y en circulación se reducirá de 47,707,849 a aproximadamente 4,770,785
- El total de acciones autorizadas disminuirá de 145,833,334 a 14,583,333
- No se emitirán acciones fraccionarias; los accionistas afectados recibirán pagos en efectivo
- El split afectará proporcionalmente a los planes de incentivos de capital, opciones sobre acciones, warrants y notas convertibles
Securities Transfer gestionará el proceso de intercambio para los accionistas con certificados físicos.
Orgenesis Inc. (Nasdaq:ORGS)는 2024년 9월 24일부터 효력을 발휘하는 1대 10 역분할 주식을 발표했습니다. 이 분할은 Nasdaq의 최소 호가 가격 요건인 주당 $1.00를 충족하기 위한 것입니다. 분할 조정 기준으로 거래는 2024년 9월 25일부터 시작되며, 기존 심볼 "ORGS" 아래에서 진행됩니다.
주요 사항:
- 발행 및 유통되는 주식 수가 47,707,849주에서 약 4,770,785주로 감소합니다
- 총 승인된 주식 수가 145,833,334주에서 14,583,333주로 줄어듭니다
- 부분 주식은 발행되지 않으며, 영향을 받는 주주들은 현금 지급을 받게 됩니다
- 분할은 자본 인센티브 계획, 주식 옵션, 워런트 및 전환 사채에 비례적으로 영향을 미칩니다
증권 이전 서비스는 물리적 증서를 가진 주주를 위한 교환 프로세스를 관리합니다.
Orgenesis Inc. (Nasdaq:ORGS) a annoncé un split inversé d'actions 1 pour 10 de ses actions ordinaires, prenant effet le 24 septembre 2024. Ce split vise à retrouver la conformité avec l'exigence de prix d'offre minimum de Nasdaq de 1,00 $ par action. Les transactions ajustées au split commenceront le 25 septembre 2024, sous le symbole existant "ORGS".
Points clés :
- Le nombre d'actions émises et en circulation sera réduit de 47 707 849 à environ 4 770 785
- Le total des actions autorisées diminuera de 145 833 334 à 14 583 333
- Aucune action fractionnée ne sera émise ; les actionnaires concernés recevront des paiements en espèces
- Le split affectera proportionnellement les plans d'incitation en capital, les options sur actions, les bons de souscription et les obligations convertibles
Securities Transfer gérera le processus d'échange pour les actionnaires avec des certificats physiques.
Orgenesis Inc. (Nasdaq:ORGS) hat einen 1-zu-10 Rückwärtssplit ihrer Stammaktien angekündigt, der am 24. September 2024 in Kraft tritt. Der Split zielt darauf ab, die Einhaltung der Nasdaq-Mindestgebotspreisanforderung von $1,00 pro Aktie wiederherzustellen. Der Handel auf Grundlage des Splits beginnt am 25. September 2024 unter dem bestehenden Symbol "ORGS".
Wichtige Punkte:
- Die Anzahl der ausgegebenen und ausstehenden Aktien wird von 47.707.849 auf ungefähr 4.770.785 reduziert
- Die Gesamtanzahl der genehmigten Aktien wird von 145.833.334 auf 14.583.333 gesenkt
- Es werden keine Bruchstücke von Aktien ausgegeben; betroffene Aktionäre erhalten Bargeldzahlungen
- Der Split wirkt sich proportional auf Eigenkapital-Anreizprogramme, Aktienoptionen, Optionsscheine und wandelbare Schuldtitel aus
Securities Transfer wird den Austauschprozess für Aktionäre mit physischen Zertifikaten verwalten.
- Potential to regain compliance with Nasdaq's minimum bid price requirement
- Maintains current trading symbol and Nasdaq Capital Market listing
- Reduction in total number of outstanding shares
- Potential for fractional shares to be cashed out, reducing some investors' holdings
GERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”) today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company’s common stock, par value
The reverse stock split is intended to regain compliance with the minimum bid price requirement of
The reverse stock split will affect all stockholders uniformly and will not alter the stockholder’s percentage ownership interest in the Company, except to the extent that the reverse stock split results in any of the Company’s stockholders owning a fractional share as described in more detail below. The reverse stock split will reduce the number of shares of common stock issued and outstanding from 47,707,849 to approximately 4,770,785. The total authorized number of shares of common stock will be proportionally reduced from 145,833,334 to 14,583,333 shares of common stock. No fractional shares will be issued in connection with the reverse stock split. Each stockholder who would otherwise be entitled to receive a fraction of a share of the Company’s common stock will be entitled to receive a cash payment based on the closing price per share of the Company’s common stock as quoted on the Nasdaq Capital Market on September 24, 2024.
As of the effective date of the reverse stock split, the number of shares of common stock available for issuance under the Company’s equity incentive plans and issuable upon the exercise of stock options, warrants and convertible notes outstanding immediately prior to the reverse stock split will be proportionately affected by the reverse stock split. The exercise prices of the Company’s outstanding options and warrants and conversion prices of the Company’s outstanding convertible notes will be adjusted in accordance with their respective terms.
Securities Transfer Corporation (“STC”), the Company's transfer agent, will act as the exchange agent for the reverse stock split. STC will provide instructions to any stockholders with physical certificates regarding the process for exchanging their certificates for split-adjusted shares into “book-entry form”. Those stockholders with common stock in “street name” will receive instructions from their brokers.
About Orgenesis:
Orgenesis is a global biotech company that has been committed to unlocking the potential of cell and gene therapies (CGTs) since 2012 as well as a paradigm-shifting decentralized approach to processing since 2020. This new model allows Orgenesis to bring academia, hospitals, and industry together to make these essential therapies a reality sooner rather than later. Orgenesis is focusing on advancing its CGTs toward eventual commercialization, while partnering with key industry stakeholders to provide a rapid, globally harmonized pathway for these therapies to reach and treat a larger numbers of patients more cost effectively and with better outcomes through great science and decentralized production. Additional information about the Company is available at: www.orgenesis.com.
Forward-Looking Statements:
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements relating to the timing, consummation, and impact of the reverse stock split, the Company’s ability to regain compliance with Nasdaq’s minimum bid price requirement, and the actions of third parties, including STC, with respect to the reverse stock split. Actual results could differ from those projected in any forward-looking statement due to numerous factors. Such factors include, among others, our ability to maintain compliance with Nasdaq’s continued listing standard, [our ability to secure additional capital, our reliance on, and our ability to grow our point-of-care cell therapy platform, our ability to achieve and maintain overall profitability, our ability to manage our research and development programs that are based on novel technologies, our ability to control key elements relating to the development and commercialization of therapeutic product candidates with third parties, the timing of completion of clinical trials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, the sufficiency of working capital to realize our business plans and our ability to raise additional capital, the development of our POCare strategy, our trans differentiation technology as therapeutic treatment for diabetes, the technology behind our in-licensed ATMPs not functioning as expected, our ability to further our CGT development projects, either directly or through our JV partner agreements, and to fulfill our obligations under such agreements, our license agreements with other institutions, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products, risks relating to legal proceedings against us] and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.
Investor relations contact for Orgenesis:
Crescendo Communications, LLC
Tel: 212-671-1021
Orgs@crescendo-ir.com
Communications contact for Orgenesis:
IB Communications Neil Hunter / Michelle Boxall
FAQ
When will Orgenesis (ORGS) implement its reverse stock split?
What is the purpose of Orgenesis' (ORGS) reverse stock split?
How will the reverse split affect Orgenesis' (ORGS) outstanding shares?